FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2545643407> ?p ?o ?g. }

• W2545643407 endingPage "1123" @default.
• W2545643407 startingPage "1119" @default.
• W2545643407 abstract "To analyze the relationship between primary tumor location and clinical response of chemotherapy in patients with metastatic colorectal cancer(mCRC).Clinical data of 721 mCRC patients who received first-line and second-line chemotherapy in Peking University Cancer Hospital between January 1996 and December 2011 were collected. All the patients were divided into 5 groups according to primary tumor location: ileocecum in 61 patients(8.5%), ascending colon or hepatic flexure in 126 patients (17.5%), transverse colon or splenic flexure in 26 patients (3.6%), descending or sigmoid colon in 172 patients (23.9%), rectum in 336 patients (46.6%). Outcomes of chemotherapy were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), including complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The overall response rate (ORR) was counted with the total number of patients divided by the number of CR+PR. Differences in first-line and second-line chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer were compared by using Chi-square test.Of the 571 patients receiving first-line chemotherapy, no one patient was classified as CR, while there were 190 as PR (33.3%), 277 as SD (48.5%) and 104 as PD (18.2%), with ORR 33.3% (190/571). The ORRs of patients with primary tumor located at ileocecum, ascending colon or hepatic flexure, transverse colon or splenic flexure, descending or sigmoid colon, rectum were 21.3% (10/47), 35.3% (36/102), 14.3% (3/21), 41.3% (57/138) and 31.9% (84/263), respectively, with statistically significant difference(P = 0.028). Difference of oxaliplatin-based first-line chemotherapy efficacy among different tumor sites was statistically significant(P = 0.009), while differences in irinotecan-based or single-agent 5-fluorouracil chemotherapy efficacy were not statistically significant (all P>0.05). In patients with primary tumor located at transverse colon or splenic flexure, irinotecan-based first-line chemotherapy had higher ORR than oxaliplatin-based or single-agent 5-fluorouracil chemotherapy, and the difference was statistically significant (P=0.042). There was no significant difference in the efficacy of different first-line chemotherapy regimens in patients with primary tumor located at other sites (all P>0.05). Of the 353 patients receiving second-line chemotherapy, no one patient was classified as CR, while there were 43 as PR (12.2%), 187 as SD (53.0%) and 123 as PD (34.8%), with ORR 12.2%(43/353). The ORRs of patients with primary tumor located at the ileocecum, the ascending colon or the hepatic flexure, the transverse colon or the splenic flexure, the descending or sigmoid colon, the rectum were 4.2%(1/24), 12.1%(8/66), 8.3%(1/12), 15.2%(12/79) and 12.3%(21/171) respectively, without statistically significant difference (P=0.686). Differences in second-line chemotherapy efficacy with the same regimen among different tumor sites were not statistically significant, and there were also no significant differences of efficacy of different second-line chemotherapy regimens in patients with the same tumor site (all P>0.05).There are differences in first-line chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer, while their second-line chemotherapy efficacy is equivalent." @default.
• W2545643407 created "2016-11-04" @default.
• W2545643407 creator A5009821208 @default.
• W2545643407 creator A5025130984 @default.
• W2545643407 creator A5059392900 @default.
• W2545643407 creator A5072537482 @default.
• W2545643407 creator A5077277862 @default.
• W2545643407 creator A5080040768 @default.
• W2545643407 date "2016-10-25" @default.
• W2545643407 modified "2023-09-22" @default.
• W2545643407 title "[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer]." @default.
• W2545643407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27781247" @default.
• W2545643407 hasPublicationYear "2016" @default.
• W2545643407 type Work @default.
• W2545643407 sameAs 2545643407 @default.
• W2545643407 citedByCount "0" @default.
• W2545643407 crossrefType "journal-article" @default.
• W2545643407 hasAuthorship W2545643407A5009821208 @default.
• W2545643407 hasAuthorship W2545643407A5025130984 @default.
• W2545643407 hasAuthorship W2545643407A5059392900 @default.
• W2545643407 hasAuthorship W2545643407A5072537482 @default.
• W2545643407 hasAuthorship W2545643407A5077277862 @default.
• W2545643407 hasAuthorship W2545643407A5080040768 @default.
• W2545643407 hasConcept C121608353 @default.
• W2545643407 hasConcept C126322002 @default.
• W2545643407 hasConcept C143998085 @default.
• W2545643407 hasConcept C2776694085 @default.
• W2545643407 hasConcept C2776870353 @default.
• W2545643407 hasConcept C2777807078 @default.
• W2545643407 hasConcept C2778292851 @default.
• W2545643407 hasConcept C2778435480 @default.
• W2545643407 hasConcept C2778822529 @default.
• W2545643407 hasConcept C2779013556 @default.
• W2545643407 hasConcept C2779984678 @default.
• W2545643407 hasConcept C2780283643 @default.
• W2545643407 hasConcept C2780833581 @default.
• W2545643407 hasConcept C2781074409 @default.
• W2545643407 hasConcept C3019760618 @default.
• W2545643407 hasConcept C526805850 @default.
• W2545643407 hasConcept C71924100 @default.
• W2545643407 hasConcept C90924648 @default.
• W2545643407 hasConceptScore W2545643407C121608353 @default.
• W2545643407 hasConceptScore W2545643407C126322002 @default.
• W2545643407 hasConceptScore W2545643407C143998085 @default.
• W2545643407 hasConceptScore W2545643407C2776694085 @default.
• W2545643407 hasConceptScore W2545643407C2776870353 @default.
• W2545643407 hasConceptScore W2545643407C2777807078 @default.
• W2545643407 hasConceptScore W2545643407C2778292851 @default.
• W2545643407 hasConceptScore W2545643407C2778435480 @default.
• W2545643407 hasConceptScore W2545643407C2778822529 @default.
• W2545643407 hasConceptScore W2545643407C2779013556 @default.
• W2545643407 hasConceptScore W2545643407C2779984678 @default.
• W2545643407 hasConceptScore W2545643407C2780283643 @default.
• W2545643407 hasConceptScore W2545643407C2780833581 @default.
• W2545643407 hasConceptScore W2545643407C2781074409 @default.
• W2545643407 hasConceptScore W2545643407C3019760618 @default.
• W2545643407 hasConceptScore W2545643407C526805850 @default.
• W2545643407 hasConceptScore W2545643407C71924100 @default.
• W2545643407 hasConceptScore W2545643407C90924648 @default.
• W2545643407 hasIssue "10" @default.
• W2545643407 hasLocation W25456434071 @default.
• W2545643407 hasOpenAccess W2545643407 @default.
• W2545643407 hasPrimaryLocation W25456434071 @default.
• W2545643407 hasRelatedWork W1996236879 @default.
• W2545643407 hasRelatedWork W2052753115 @default.
• W2545643407 hasRelatedWork W2235371377 @default.
• W2545643407 hasRelatedWork W2490453394 @default.
• W2545643407 hasRelatedWork W2518613010 @default.
• W2545643407 hasRelatedWork W2545643407 @default.
• W2545643407 hasRelatedWork W2610719567 @default.
• W2545643407 hasRelatedWork W2744203203 @default.
• W2545643407 hasRelatedWork W2986505932 @default.
• W2545643407 hasRelatedWork W3181087562 @default.
• W2545643407 hasVolume "19" @default.
• W2545643407 isParatext "false" @default.
• W2545643407 isRetracted "false" @default.
• W2545643407 magId "2545643407" @default.
• W2545643407 workType "article" @default.